Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Bischoff J, et al. Among authors: schulze zur wiesch j. J Clin Gastroenterol. 2020 Feb;54(2):192-199. doi: 10.1097/MCG.0000000000001189. J Clin Gastroenterol. 2020. PMID: 30789853
Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.
Schulze Zur Wiesch J, Thomssen A, Hartjen P, Tóth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk S, Babikir D, Schmiedel S, Degen O, Mauss S, Rockstroh J, Staszewski S, Khaykin P, Strasak A, Lohse AW, Fätkenheuer G, Hauber J, van Lunzen J. Schulze Zur Wiesch J, et al. J Virol. 2011 Feb;85(3):1287-97. doi: 10.1128/JVI.01758-10. Epub 2010 Nov 3. J Virol. 2011. PMID: 21047964 Free PMC article.
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.
Wehmeyer MH, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, van Lunzen J, Lohse AW, Schulze zur Wiesch J, Lüth S. Wehmeyer MH, et al. Among authors: schulze zur wiesch j. BMC Gastroenterol. 2014 May 5;14:87. doi: 10.1186/1471-230X-14-87. BMC Gastroenterol. 2014. PMID: 24884400 Free PMC article.
Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV.
Platten M, Jung N, Trapp S, Flossdorf P, Meyer-Olson D, Schulze Zur Wiesch J, Stephan C, Mauss S, Weiss V, von Bergwelt-Baildon M, Rockstroh J, Fätkenheuer G, Lehmann C. Platten M, et al. Among authors: schulze zur wiesch j. AIDS Res Hum Retroviruses. 2016 Jun;32(6):579-87. doi: 10.1089/AID.2015.0226. Epub 2016 Feb 22. AIDS Res Hum Retroviruses. 2016. PMID: 26751176
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer MH, Boesecke C, Simon KG, Berger F, Rockstroh JK, Schulze zur Wiesch J, Baumgarten A, Mauss S. Ingiliz P, et al. Among authors: schulze zur wiesch j. Clin Infect Dis. 2016 Nov 15;63(10):1320-1324. doi: 10.1093/cid/ciw567. Epub 2016 Aug 17. Clin Infect Dis. 2016. PMID: 27535952 Clinical Trial.
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Wehmeyer MH, et al. Among authors: schulze zur wiesch j. J Med Virol. 2018 Feb;90(2):304-312. doi: 10.1002/jmv.24903. Epub 2017 Nov 9. J Med Virol. 2018. PMID: 28710853
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Berg T, et al. Among authors: schulze zur wiesch j. J Hepatol. 2017 Nov;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012. Epub 2017 Jul 21. J Hepatol. 2017. PMID: 28736139 Clinical Trial.
218 results